Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: A meta-analysis of randomized controlled trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, G.G. | - |
dc.contributor.author | Bae, S.-C. | - |
dc.contributor.author | Lee, Y.H. | - |
dc.date.accessioned | 2021-08-02T18:29:25Z | - |
dc.date.available | 2021-08-02T18:29:25Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2014-09 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/25781 | - |
dc.description.abstract | Background/Aims The aim of this study was to assess the efficacy and safety of tofacitinib (5 and 10 mg twice daily) in patients with active rheumatoid arthritis (RA). Methods A systematic review of randomized controlled trials (RCTs) that examined the efficacy and safety of tofacitinib in patients with active RA was performed using the Medline, Embase, and Cochrane Controlled Trials Register databases as well as manual searches. Results Five RCTs, including three phase-II and two phase-III trials involving 1,590 patients, met the inclusion criteria. The three phase-II RCTs included 452 patients with RA (144 patients randomized to 5 mg of tofacitinib twice daily, 156 patients randomized to 10 mg of tofacitinib twice daily, and 152 patients randomized to placebo) who were included in this meta-analysis. The American College of Rheumatology 20% response rate was significantly higher in the tofacitinib 5- and 10-mg groups than in the control group (relative risk [RR], 2.445; 95% confidence interval [CI], 1.229 to 4.861; p = 0.011; and RR, 2.597; 95% CI, 1.514 to 4.455; p = 0.001, respectively). The safety outcomes did not differ between the tofacitinib 5- and 10-mg groups and placebo groups with the exception of infection in the tofacitinib 10-mg group (RR, 2.133; 95% CI, 1.268 to 3.590; p = 0.004). The results of two phase-III trials (1,123 patients) confirmed the findings in the phase-II studies. Conclusions Tofacitinib at dosages of 5 and 10 mg twice daily was found to be effective in patients with active RA that inadequately responded to methotrexate or disease-modifying antirheumatic drugs, and showed a manageable safety profile. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Korean Association of Internal Medicine | - |
dc.title | Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: A meta-analysis of randomized controlled trials | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Bae, S.-C. | - |
dc.identifier.doi | 10.3904/kjim.2014.29.5.656 | - |
dc.identifier.scopusid | 2-s2.0-84907157319 | - |
dc.identifier.wosid | 000341125800015 | - |
dc.identifier.bibliographicCitation | Korean Journal of Internal Medicine, v.29, no.5, pp.656 - 663 | - |
dc.relation.isPartOf | Korean Journal of Internal Medicine | - |
dc.citation.title | Korean Journal of Internal Medicine | - |
dc.citation.volume | 29 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 656 | - |
dc.citation.endPage | 663 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001908365 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.subject.keywordPlus | alanine aminotransferase | - |
dc.subject.keywordPlus | aspartate aminotransferase | - |
dc.subject.keywordPlus | C reactive protein | - |
dc.subject.keywordPlus | disease modifying antirheumatic drug | - |
dc.subject.keywordPlus | methotrexate | - |
dc.subject.keywordPlus | placebo | - |
dc.subject.keywordPlus | tofacitinib | - |
dc.subject.keywordPlus | antirheumatic agent | - |
dc.subject.keywordPlus | Janus kinase | - |
dc.subject.keywordPlus | piperidine derivative | - |
dc.subject.keywordPlus | protein kinase inhibitor | - |
dc.subject.keywordPlus | pyrimidine derivative | - |
dc.subject.keywordPlus | pyrrole derivative | - |
dc.subject.keywordPlus | tofacitinib | - |
dc.subject.keywordPlus | alanine aminotransferase blood level | - |
dc.subject.keywordPlus | American College of Rheumatology response rate | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | aspartate aminotransferase blood level | - |
dc.subject.keywordPlus | Cochrane Library | - |
dc.subject.keywordPlus | drug dose comparison | - |
dc.subject.keywordPlus | drug efficacy | - |
dc.subject.keywordPlus | drug safety | - |
dc.subject.keywordPlus | drug treatment failure | - |
dc.subject.keywordPlus | Embase | - |
dc.subject.keywordPlus | Health Assessment Questionnaire | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | infection | - |
dc.subject.keywordPlus | liver dysfunction | - |
dc.subject.keywordPlus | liver function test | - |
dc.subject.keywordPlus | lung tuberculosis | - |
dc.subject.keywordPlus | Medline | - |
dc.subject.keywordPlus | meta analysis | - |
dc.subject.keywordPlus | named inventories, questionnaires and rating scales | - |
dc.subject.keywordPlus | pain assessment | - |
dc.subject.keywordPlus | phase 2 clinical trial (topic) | - |
dc.subject.keywordPlus | phase 3 clinical trial (topic) | - |
dc.subject.keywordPlus | randomized controlled trial (topic) | - |
dc.subject.keywordPlus | rheumatoid arthritis | - |
dc.subject.keywordPlus | systematic error | - |
dc.subject.keywordPlus | systematic review | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordPlus | treatment response | - |
dc.subject.keywordPlus | visual analog scale | - |
dc.subject.keywordPlus | antagonists and inhibitors | - |
dc.subject.keywordPlus | Arthritis, Rheumatoid | - |
dc.subject.keywordPlus | Antirheumatic Agents | - |
dc.subject.keywordPlus | Arthritis, Rheumatoid | - |
dc.subject.keywordPlus | Clinical Trials, Phase II as Topic | - |
dc.subject.keywordPlus | Clinical Trials, Phase III as Topic | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Janus Kinases | - |
dc.subject.keywordPlus | Methotrexate | - |
dc.subject.keywordPlus | Piperidines | - |
dc.subject.keywordPlus | Protein Kinase Inhibitors | - |
dc.subject.keywordPlus | Pyrimidines | - |
dc.subject.keywordPlus | Pyrroles | - |
dc.subject.keywordPlus | Randomized Controlled Trials as Topic | - |
dc.subject.keywordPlus | Treatment Outcome | - |
dc.subject.keywordAuthor | Arthritis | - |
dc.subject.keywordAuthor | Efficacy | - |
dc.subject.keywordAuthor | Rheumatoid | - |
dc.subject.keywordAuthor | Safety | - |
dc.subject.keywordAuthor | Tofacitinib | - |
dc.identifier.url | https://www.kjim.org/journal/view.php?doi=10.3904/kjim.2014.29.5.656 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.